Drug Profile
Research programme: inhaled therapeutics - Acorda Therapeutics
Alternative Names: Inhaled zolmitriptan - Acorda TherapeuticsLatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Civitas Therapeutics
- Developer Acorda Therapeutics
- Class Catecholamines; Tryptamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypersensitivity; Lung disorders; Pain